Adverse reactions: Evaluated in 2460 postmenopausal women with osteoporosis1

This study was not designed to provide head-to-head comparative efficacy data and
cannot be interpreted as evidence of superiority or noninferiority to teriparatide.1

Adverse reactions reported by patients treated with TYMLOS vs placebo
  • This study compared TYMLOS vs placebo and teriparatide vs placebo.
    It did not compare TYMLOS vs teriparatide1
  • The incidence of serious adverse events (SAEs) was 10% (TYMLOS),
    11% (placebo), and 10% (teriparatide)1,2
    • There were no discernible differences in SAEs between treatment groups3
    • No single SAE occurred in >0.5% of patients in the TYMLOS or placebo groups3
    • None of the SAEs were classified by investigators as being related
      to the study medication in the TYMLOS or placebo groups3

Discontinuation rates1

  • Discontinuation rates due to adverse events were 10% (TYMLOS),
    6% (placebo), and 7% (teriparatide)1,2
    • In the TYMLOS group, the most common ARs leading to drug discontinuation
      were nausea (2%), dizziness (1%), headache (1%), and palpitations (1%)2

These data represent the most common ARs in the study; ARs were generally not present at baseline, occurred more commonly with TYMLOS than with placebo, and occurred in at least 2% of the patients treated with TYMLOS.2

Hypercalcemia was predefined as albumin-corrected serum calcium level of at least 10.7 mg/dL (or ≥2.67 mmol/L).1

References: 1. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.] 2. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 3. Data on file. Radius Health, Inc; Waltham, MA.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.   All rights reserved.    04/18.   TYM-US-01391

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.
All rights reserved. 04/18.
TYM-US-01391

Back to Top